Conformis, Inc. to Participate in the 2020 Oppenheimer Fall MedTech Summit
Conformis, Inc. (NASDAQ:CFMS) announced participation in the virtual 2020 Oppenheimer Fall MedTech Summit on November 12, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Conformis, Inc. (NASDAQ:CFMS) announced participation in the virtual 2020 Oppenheimer Fall MedTech Summit on November 12, 2020. Mark Augusti, President and CEO, and Robert Howe, CFO, will hold one-on-one meetings during the event.
Conformis specializes in personalized medical technology, using its proprietary iFit Image-to-Implant platform to create customized joint replacement implants and instruments. The iTotal CR knee replacement system shows superior clinical results in function and patient satisfaction compared to traditional implants.
Details
News Market Reaction – CFMS
The recorded move for CFMS in the trading session of this news was +2.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BILLERICA, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will participate in the virtual 2020 Oppenheimer Fall MedTech Summit taking place Thursday, November 12, 2020, in one-on-one meetings.
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.